Guidelines

A-111 CLOPIDOGREL PREVENTS COLITIS-ASSOCIATED CARCINOGENESIS IN MICE BY INHIBITING IMMUNOSUPPRESSIVE FUNCTION OF IMMATURE MYELOID CELLS

February 2017
A-140 STAPHYLOCOCCUS AUREUS AND STAPHYLOCOCCUS LUGDUNENSIS BIND VON WILLEBRAND FACTOR TO OVERCOME SHEAR STRESS AND CAUSE ENDOCARDITIS

February 2017
A-103 VALIDATION OF A CHROMOGENIC ASSAY FOR FVIII: C AND FIX: C (CSA) MEASURING AND COMPARISON WITH A CHRONOMETRIC ASSAY (OSA)

February 2017
A-115 ACQUIRED VON WILLEBRAND SYNDROME AFTER LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION

February 2017
A-137 COAGULATION FACTOR IX INHIBITOR DETERMINATION REVISITED: PRACTICAL EVALUATION OF THE ANTI-FIX BETHESDA ASSAY.

February 2017
A-139 COMPARISON OF 4T-SCORE AND LABORATORY TESTS IN THE DIAGNOSIS OF HIT

February 2017
A-138 COMPARISON OF ACTIVATED CLOTTING TIME MEASURED BY I-STAT, SONOCLOT AND ACTPLUS AND CORRELATION WITH ANTI-XA DURING CARDIOPULMONARY BYPASS PROCEDURES

February 2017
A-116 EVALUATION OF THE CLINICAL PERFORMANCE OF TWO AUTOMATED IMMUNOASSAYS IN THE DIAGNOSIS OF THROMBOTIC ANTIPHOSPHOLIPID SYNDROME

February 2017
A-141 INTERFERENCE OF CRP IN LUPUS ANTICOAGULANS TESTING: IS CRP THE ONLY CAUSE?

February 2017
A-102 PERFORMANCE EVALUATION OF THE NEW POINT-OF-CARE COAGULATION ANALYZER XPRECIA STRIDE FOR MEASURING INR IN VKA-TREATED PATIENTS – COMPARISON WITH LOCAL LABORATORY AUTOMATED REFERENCE METHOD

February 2017

Top